EXEL Strong Performance & Record Cancer Drug Sales

Exelixis, Inc. (EXEL) reported a significant increase in Q1 profit, driven by record sales of its cancer drug, Cabometyx. The company's earnings totaled $210.47 million, or $0.79 per share, up from $159.62 million, or $0.55 per share, in the same period last year. Adjusted earnings also rose, reflecting the drug's strong performance.

This development has a positive impact on the cancer drug market, with EXEL's stock price increasing following the earnings report. The company's strong performance may encourage investors to explore other biotechnology and pharmaceutical companies with promising cancer drug pipelines.

Investors should watch for EXEL's full-year 2023 guidance, expected in the upcoming earnings call, to gauge the company's confidence in maintaining this growth trajectory. Additionally, the U.S. Food and Drug Administration's (FDA) decision on EXEL's supplemental New Drug Application (sNDA) for Cabometyx in non-metastatic renal cell carcinoma, expected in Q2 2023, could further influence the stock's performance.